Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
出版年份 2019 全文链接
标题
Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
作者
关键词
Breast cancer, Hormone receptor-positive breast cancer, HER2 positive breast cancer, Triple negative breast cancer, Immunotherapy, Immune checkpoint inhibitors, PD1, PD-L1, CTLA-4, Pembrolizumab, Nivolumab, Ipilimumab, Avelumab, Durvalumab, Atezolizumab, PARP inhibitors, BRCA1/2 mutations, Tumor-infiltrating lymphocytes
出版物
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 20, Issue 4, Pages -
出版商
Springer Nature
发表日期
2019-03-28
DOI
10.1007/s11864-019-0634-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Recurrent Glioblastoma Treated with Recombinant Poliovirus
- (2018) Annick Desjardins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.
- (2018) Jeremy Force et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
- (2018) Siddhartha Devarakonda et al. JOURNAL OF CLINICAL ONCOLOGY
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
- (2018) Alexandra Thomas et al. OncoImmunology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Rationale for stimulator of interferon genes–targeted cancer immunotherapy
- (2017) Thaiz Rivera Vargas et al. EUROPEAN JOURNAL OF CANCER
- Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
- (2017) Zishuo I. Hu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Breast cancer
- (2017) Nadia Harbeck et al. LANCET
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs
- (2017) Michael C. Brown et al. Science Translational Medicine
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
- (2017) Emma Nolan et al. Science Translational Medicine
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
- (2016) H. L. McArthur et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015
- (2016) Shelley McGuire Advances in Nutrition
- Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
- (2016) D. B. Page et al. Cancer Immunology Research
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions
- (2015) Marat D. Kazanov et al. Cell Reports
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- (2014) F. Cardoso et al. BREAST
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Pertuzumab
- (2012) Gillian M. Keating DRUGS
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Triple-Negative Breast Cancer: An Unmet Medical Need
- (2011) C. A. Hudis et al. ONCOLOGIST
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now